 
 
Microscopic Fluorescence -guided Vestibular 
Schwannoma Resection Using Fluorescein 
Sodium and YELLOW 560   
 
[STUDY_ID_REMOVED]  
 
November 25, 2021  
Clinical Investigation Plan   
Microscopic Fluorescence -guided Vestibular Schwannoma , 
Meningioma, Head and Neck Paraganglioma, or Head and Neck 
Schwannoma  Resection using Fluorescein Sodium and YELLOW 560 
Mayo Clinic, Rochester, Minnesota, USA  
 
 
Version 1. 3 
Updated November 25, 2021  
  
TABLE OF CONTENTS  
1.0 Introduction  ............................................................................................................................................ 3 
1.1. Statement  .............................................................................................................................................. 3 
1.2 Definitions ............................................................................................................................................... 3 
1.3. Purpose  .................................................................................................................................................. 4 
1.4. Application  ............................................................................................................................................ 4 
1.5. Responsibility and Authority  ................................................................................................................. 5 
2. Details of the clinical Investigation ......................................................................................................... 5 
2.1. Principal Investigator  ............................................................................................................................ 5 
2.1.1. Co -Investigators  ................................................................................................................................. 5 
2.2. Institution where investigation will be conducted  ............................................................................... 6 
2.3. Analysis of the Study Data  .................................................................................................................... 6 
2.4. Sponsor of the Clinical Investigation  .................................................................................................... 6 
2.5. Database Management  ........................................................................................................................ 6 
2.6. Security of Patient Data  ........................................................................................................................ 6 
2.7. Verification of Source Data  ................................................................................................................... 7 
2.8. Data Storage  ......................................................................................................................................... 7 
2.9. Data Retention  ...................................................................................................................................... 7 
3. Overview of the clinical Investigation  ..................................................................................................... 7 
3.1. Objectives  .............................................................................................................................................. 7 
3.2. Literature Review and Rationale  .......................................................................................................... 7 
3.3. References  ............................................................................................................................................. 8 
3.4. Hypothesis  ............................................................................................................................................. 9 
3.5. Design and Proposed Analysis  .............................................................................................................. 9 
3.6. Methodology  ....................................................................................................................................... 10 
3.6.1. Investigational Type  ......................................................................................................................... 10 
3.6.10. Primary safety endpoints  ............................................................................................................... 11 
3.6.11. Microscope imaging during YE560 fluorescence use  .................................................................... 12 
3.6.2. Patients  ............................................................................................................................................. 10 
3.6.3. Timeframe  ........................................................................................................................................ 10 
3.6.4. Recruitment Process  ......................................................................................................................... 10 
3.6.5. Inclusion Criteria .............................................................................................................................. 10 
3.6.6. Exclusion Criteria .............................................................................................................................. 11 
3.6.7. Point of Enrollment  .......................................................................................................................... 11 
3.6.8. Primary Endpoint  ............................................................................................................................. 11 
3.6.9. Secondary Endpoints  ........................................................................................................................ 11 
3.7. Informed Consent Process  ................................ ................................................................................... 12 
3.8. Monitoring and Execution of the Trial ................................................................................................ 12 
3.9. Record Keeping  .................................................................................................................................... 13 
4. Descri ption of the Medical Device under Investigation........................................................................ 13 
4.1. Manufacturer  ...................................................................................................................................... 13 
4.2. Item/Part Number  ............................................................................................................................... 13 
4.3. Intended Purpose of this Device  ......................................................................................................... 13 
4.4. Clinical Indications & Contraindications for use in Study  .................................................................. 14 
4.5. Summary of Device Design  ................................................................................................................. 14 
5. Training and Expe rience Requirements for use of the Device  .............................................................. 15 
6. Description of Medical/Surgical Procedures involved in the use of the device  ................................... 15 
7. Study Drug  .............................................................................................................................................. 15 
7.1. Description  ........................................................................................................................................... 15 
7.2. Method for Assigning Subjects to Study Group ................................................................................. 16 
7.3. Preparation and Administration of Study Drug ................................................................................. 16 
7.4. Subject Compliance and Adverse Event Monitoring .......................................................................... 16 
7.4.1. Subject Compliance  .......................................................................................................................... 17 
7.4.2. Adverse Event Monitoring  ............................................................................................................... 17 
7.4.3. Adverse Event Reporting  .................................................................................................................. 17 
7.5. Packaging  ............................................................................................................................................ 17 
7.6. Receiving, Storage, Dispensing and Return  ....................................................................................... 17 
7.6.1. Receiving of Drug Supplies  ............................................................................................................... 17 
7.6.2. Storage  ............................................................................................................................................. 17 
7.6.3. Dispensing of Study Drug  ................................................................................................................. 17 
7.6.4. Return or Destruction of Study Drug  ............................................................................................... 17 
8. Clinical Investigation and Documentation ............................................................................................ 17 
8.1. Requirements before Starting the Clinical Investigation  ................................................................... 17 
8.2. Trai ning and Information for Clinical Investigators  ........................................................................... 18 
8.3. Investigator and Sponsor File Maintained ......................................................................................... 18 
8.4. Final Report  ......................................................................................................................................... 18 
APPENDIX 1 ................................................................................................................................................. 19 
APPENDIX 2 ................................................................................................................................................. 20 
APPENDIX 3 ................................................................................................................................................. 21 
 
  
1.0 Introduction  
1.1. Statement   
The study will be conducted according to US and international standards of Good Clinical Practice (FDA 
Title 21 part 312) and International Conference on Harmonization guidelines, applicable government regulations and institutional (Mayo Clinic) research policies and procedures . 
1.2 Definitions
 
Term  Description  
YE560  YELLOW 560 fluorescence module (available 
for KINEVO  900)  
CIP  Clinical Investigation Plan  
CRF  Case Report Form  
AEF  Adverse Event Form  
Device Manufacturer  Carl-Zeiss Meditec AG (Jena, Germany)  
FDA  Food and Drug Administration  
IDE  Investigational Device Exemption  
IRB  Institutional Review Board  
OR  Operating Room  
Sponsor  Carl Zeiss Meditec, Inc. (Dublin, CA)  
VS Vestibular Schwannoma   
GTR Gross Total Resection  
HNP  Head and Neck Paraganglioma  
HNS  Head and Neck Schwannoma  
 
1.3. Purpose   
The purpose of this study is:  
• To evaluate the benefit of using intravenous fluorescein sodium  (FS) and YELLOW 560 nm 
microscope filter (YE560) during surgery for vestibular schwannomas (VS)  menigioma, head and 
neck paraganglioma (HNP) , or head and neck schwannoma  (HNS)  
• To determine the optimum FS dose and timing to be used with the YE560 device  
VSs are benign, slow -growing neoplasms of the myelin- containing Schwann cells of the vestibular 
division of the vestibulocochlear nerve. These tumors are in close proximity to the  facial nerve and 
cochlear division of the vestibulocochlear nerve. These nerves allow for facial movement and hearing, 
respectively. Management of these indolent tumors has shifted to more conservative means of minimizing growth and maintaining facial function and hearing. Management of VS s include s 
observation with serial MRI exams, stereotactic radiosurgery, and microsurgery.  
Similarly, HNP , HNS and skull base meningiomas are benign but infiltrative tumors that grow adjacent to 
important neurovascular st ructures including, the cranial nerves. These tumors can be observed, treated 
with radiosurgery, or microsurgery based on size, symptoms, and patient preference.  
When microsurgical resection of VS, schwannomas,  meningiomas, or paragangliomas  is performed, 
distinguishing the tumor from healthy nerve tissue is performed via direct visualization under light 
microscopy and tissue manipulation. Often, the se tumors are intimately associated with the surrounding 
nerves , and can be difficult to distinguish under the microscope. In many cases i ntraoperative cranial 
nerve monitoring allow for the use of a stimulation probe to help make this distinction.    
The hypothesis is that FS and YE560 may be used as a supplementary v isualization aid to better 
distinguish the tumor from healthy nerve tissue and secondarily improve conservation of facial and 
hearing nerve function and attainment of gross total resection (GTR).  Use of intravenous FS has FDA 
approval for ophthalmologic applications and its safety profile is well documented  (Yanuzzi 1986) . There 
have been studies demonstrating uptake of FS by VS tissue in vitro (Perez 2018). Additionally, the 
feasibility and utility of intraoperative fluorescence from FS intravenous adminis tration  and use of YE560 
have  been demonstrated with peripheral schwannomas in vivo (Pedro 2019). The YE560 fluorescence 
module available for the KINEVO  900 will be used to visualize fluorescein -stained tissue in yellow light.  
FS will be administered upon initial visualization of the VS. Utility of FS and YE560 will be assessed via 
surgeon survey, correlation with biopsy of fluorescent VS tissue, and color image analysis of healthy and 
VS tissue using the YE560.  
A total of  90 consenting patients, either mal e or female, clinically indicated for resection of a suspected 
VS will be enrolled into the study. No exclusions will be made for recurrent VS following stereotactic 
radiosurgery or microsurgical resection or VS associated with neurofibromatosis type 2 (NF -2). 
1.4. Application   
The document appl ies to the YE560  Fluorescence option available for KINEVO  900 supplied for the 
intended clinical investigation and protocol at the specified hospital site. The Clinical Investigation Plan 
(CIP; or Sponsor Protocol) must be agreed to by the Sponsor and Clinical Investigators involved in the study. 
 
1.5. Responsibility and Authority   
Mayo Clinic  Institutional Review Board (IRB) for Human Research must grant approval of the study, and 
record their determination of the study’s risk profile as a non- significant or significant risk medical 
device study.  
Clinical investigators, research collaborators, and Carl Zeiss Meditec, Inc staff involved in the study are responsible for implementing the described procedures.  
2. Details of the clinical Investigation   
 
2.1. Principal Investigator  
 
Matthew L. Carlson, MD  
Professor  of Otorhinolaryn ology  and Neurosurgery  
Mayo Clinic - Rochester  
200 F irst Street SW  
Rochester, MN 55905 , USA  
 
2.1.1. Co -Investigator s  
Colin L. W. Driscoll, MD  
Brian A. Neff, MD  
Stephen A. Chan, MD  
Michael J. Link, MD  
Jamie J. Van Gompel, MD  
Cynthia Chweya  
 Mayo Clinic - Rochester
 
200 First Street SW  
Rochester, MN 55905 , USA  
2.2. Institution where investigation will be conducted  
Mayo Clinic  
Rochester , Minnesota , USA  
2.3. Analysis of the Study Data  
The Study results will be analyzed by:  
• Clinical Investigator at Mayo Clinic ( Rochester, MN , USA)  
2.4. Sponsor of the Clinical Investigation   
Carl Zeiss Meditec, Inc.  
5160 Hacienda Dr,  
Dublin, CA 94568  
Data and Quality Management  
2.5. Database Management   
Clinical Investigators  shall be responsible for day -to-day database management, keeping a secure record 
of all patients recruited for the purposes of the study and details of the procedure performed. All data 
generated from this clinical study will comply with Federal Drug and Food Administration (FDA) compliant guidelines. 
 
2.6. Security of Patient Data  
Patients will be assigned unique identifiers codes upon enrollment.   Digital images and videos captured 
from surgery will be saved on a department drive in a folder with limited access.  Electronic data will be 
stored in Rave Electronic Data Capture (Medidata, New York, NY). Digital images, raw procedure data, photos, macroscopic images, video, other imaging data (e.g. MRI, CT), medical histo ry or histopathology 
data used in  publication will not contain any information that identifies individual subjects.
    
2.7. Verification of Source Data  
Digital images that are collected are saved in jpeg format for images and mpeg -2 format for videos as a 
procedure result, which is associated with a unique session ID number. Images and videos may be exported from the microscope and saved in various common  image file formats (e.g. jpg, bmp, tif). 
Source data can be verified by viewing images in the original saved format (Procedure Result) via the instrument software. 
 
2.8. Data Storage   
Data will be collected from surgeon surveys and the medical record and recorded electronically in Rave Electronic Data Capture (Medidata, New York,  NY), a product in compliance with FDA 21 CFR Part 11. Only authorized research staff will have access to th e electronic data. Paper copies of informed consent 
forms and completed  surgeon surveys will be stored in a binder kept by the study coordinator.  
2.9. Data Retention 
 
The principal investigator will retain clinical research data for 3 years after completion and closure of the 
study . 
3. Overview of the clinical Investigation   
3.1. Objectives   
Primary objective of this initial feasibility study is to evaluate the benefit of using YE560  to visualize 
fluorescein sodium  (FS) during surgery of VS, Meningioma, HNP, or HNS, determined from surgeon 
assessment.   
Secondary objectives are:  
• To evaluate the optimum FS dose and timing to be used with the YE560 device as determined by 
reported performance on surgeon surveys  
• Quantify tissue differentiation of fluorescent VS and adjacent nerves using RGB image analysis 
• To report clinical outcomes, including GTR rates, postoperative hearing outcomes, and postoperative 
facial nerve function   
 
3.2. Literature Review and Rationale   
In VS cases where intervention is recommended, stereotactic radiosurgery and microsurgical resection 
offer two therapeutic op tions. Comparatively, microsurgical resection carries the advantage of offering 
the highest chance of a cure .The goal of surgery remains to resect the tumor while maintaining the  
integrity of the  adjacent, and sometimes intimately adherent cochlear and facial nerves. Thus, gross 
total resection cannot always be achieved.  Nakatomi and colleagues described the superior 15 -year 
recurrence -free survival rates  in patients receiving gross total resection (56%) versus subtotal resection 
(8%).1  Intraoperatively, maximum resection of the tumor while preserving facial function and hearing 
relies on the ability to distinguish normal nerve tissue and tumor. Additional means of distinguishing  
these tissues could facilitate greater rates of gross total resection and preservation of cranial nerve 
function.  
Intravenous FS has been used in ophthalmologic and neurosurgical applications to differentially cause 
fluorescence in tissues intraoperatively. This technique was reported in 1948 by Moore et al2 and more 
recently by Koc and Toda in obtaining gross total resection of high grade gliomas3,4.  Fluore scein 
angiography has been routinely used for retinal imaging for vascular conditions and neoplasms  since 
first described in 1961.5  
As previously mentioned, t wo recent studies have demonstrated the application of intravenous FS  to 
VSs. Perez et al have reported in vitro preferential uptake of FS in VS cells compared to native Schwann 
cells.6  Additiona lly, Pedro et al demonstrated feasibility of YE560 and intravenous FS in visualizing 
benign peripheral nerve sheath tumors —an identical histological entity  to VS —located in the 
extremities.7 In our  proposed  study, the fluorescence light will be visualized with a surgical microscope 
(Kinevo 900 ) with Y E560 fluorescence module. The device has optimized filter and optics; therefore, the 
concentration of fluorescein sodium per patient used in this study is expected to be lower than in earlier 
studies  that do not use the fluorescence module.  
Intraoperative fluorescence imaging has been utilized in the resection of HNP and meningiomas. 
Indocyaningreen fluorescence angiography has been used to assess post -embolization vascularity of 
paraganglioma to est imate bleeding risk.8 FS has been utilized with the YE560 to distinguish meningioma 
and hyperostosis from surrounding brain and healthy bone.9 
FS is FDA approved for ophthalmologic applications. The standard  dose for retinal imaging in adults is a 
500 mg b olus into a peripheral vein (7.1 mg/kg in a 70 kg patient) .10  The safety profile of intravenous FS  
is well- described in the ophthalmology literature. Nausea and vomiting are  the most common side effect 
reported , but 87% of sur veyed ophthalmologists report ed rates less than 5%. Urticaria is estimated to 
occur at a rate of 1 in 82 patients. Severe adverse reactions, including res piratory reactions (1:3,800), 
cardiac events (1:5300), and tonic -clonic  seizure  (1:13.900)  are rare and estimated to occur  cumulati vely 
in 1 in 1900 pa tients .11 
 
3.3. References  
1. Nakatomi H, Jacob JT, Carlson, ML, Tanaka S, Tanaka M, Saito N, Lohse CM, Driscoll CLW, Link 
MJ. Long- term risk of recurrence and regrowth after gross -total and subtotal resection of 
sporadic vestibular schwannoma. J Neurosurg. 2017. 1 -7. 
2. Moore GE, Peyton WT, Lyle  A, French MD, Walker WW. The clinical use of fluorescein in 
neurosurgery; the localization of brain tumors. 1948. J Neurosurg. 5(4): 392 -8. 
3. Koc K, Anik I, Cabuk B, Ceylan  S. Fluorescein sodium –guided surgery in glioblastoma multiforma: 
a prospective evaluation. Br J Neurosurg. 2008. 22(1):99 -103.  
4. Toda M. Intraoperative navigation and fluorescence imaging in malignant glioma surgery. Keo J 
Med. 2008. 57(3)155- 161.  
5. Novotny HR, Alvis DL. A method of photographing fluorescence in circulating blood in the 
human retina. Circulation 1961; 24(1):82 -86. 
6. Perez, ER, Bracho O, Ein L, Szczupak M, Monje PV, Fernandez- Valle C, Alshaiji A, Ivan M, Morcos 
J, Liu XZ, Hoffer M, Eshraghi A, Angeli S, Telischi F, Dinh CT. Fluorescent Detection of merlin -
deficient schwann cells and primary human vestibular schwannoma cells using sodium fluorescein. Otol and Neurotolog. 2018. 39: 1053 -59. 
7. Pedro MT, Eissler A, Schmidberger J, Kratzer W, Wirtz CR, Antoniadis G, Koenig RW. Sodium fluorescein -guided surgery in peripheral nerve sheath tumors:first experience in 10 cases of 
schwannoma. World Neurosurg. 2019. E1 -E9.  
8. Siedeck V, Waggershauser T, Berghaus A, Matthias C. Intraoperative monitoring of intraarterial 
paraganglioma embolization by indocyaningreen fluorescence angiography. Eur Arch 
Otorhinolarnygol (2009) 266: 1449- 1454.  
9. Akcakaya MO, Goker B, Kasimcan MO, Hamamamcioglu MK, Kiris T. Use of Sodium Fluorescein 
in Meningioma Surgery Performed Under th e YELLOW -560 nm Surgical Microscope filter: 
Feasibility and preliminary results. World Neurosurgery. 2017. 107: 966 -973.  
10. “Fluorescein drug summary.” Prescribers’ Digital reference. Downloaded 5/20/19. <https://www.pdr.net/drug- summary/Fluorescite -fluorescein -1002>  
11. Yannuzzi LA, Rohrer KT, Tindel LJ, Sobel RS, Costanza MA, Shields W, Zhang E. Fluorescein 
Angiography Complication Survey. Ophthalmology 1986. 93(5):611- 17 
 
3.4. Hypothesis   
12. Given prior evidence of preferential uptake of FS in VS and meningiomas due to disrupted blood 
brain barrier, we hypothesize that use of intravenous FS will allow for visual differentiation of tumor  and surrounding structures and nerves using YE560.  
13. The o ptimal dosing for FS has not been established for this application. Pedro et al utilized 0.5 -
1.0 mg/kg body weight to visualize peripheral nerve sheath tumors with YE560.  The authors 
found saturation of all tissues with 3 -4 mg/kg dose within 18 seconds of administration. The 
blood -brain barrier may play a modulating role. Schebesch et al (2013) used 3 -4 mg/kg to 
visualize malignant gliomas and observed fluorescence after 20 -30 minutes. We suspect that the 
optimal dose will be 3 -4 mg/kg, and peak fluorescenc e will take a similar amount of time. 
However, w e will initially utilize 1.0 mg/kg SF administered at the time of first visualizing the 
tumor to enable subsequent doses  (up to a maximum of 500 mg  or 7 mg/kg ). This will allow us 
to determine the minimum eff ective dose and observe the time to peak fluorescence. The 
optimal dosing strategy will be finalized after the first 10 cases . 
14. We hypothesize that the surgeons will be satisfied with the use of SF and YE560, as reflected in 
responses on the Surgeon Survey.  Specifically, we hypothesize that greater than 75% of 
surgeons would choose to use SF and YE560 at least in the majority of future VS , meni goma, 
HNP, or HNS resections based on responses from the Surgeon Survey.  Secondarily, we 
hypothesize that surgeons will rate the correlation of fluorescence with visual assessment with white light microscopy and electrostimulation to be “good” or “excellent” for over 75% of the cases. 
15.  Because the yellow fluorescence is primarily comprised of red and green components, we 
hypothesize that RGB component analysis of intraoperative images will yield significantly higher red and green values in the VS compared to the facial and cochlear nerves.  Similar analysis may 
be conducted between the tumor and surround nerves or structures of interest for  meningiomas, HNP, and HNS.  
   
3.5. Design and Proposed Analysis   
16. The feasibility study will involve 90  patients, focusing on intra- operative visualization of 
fluorescein using YE560  in VS, meni gioma, HNP , or HNS,  inclusive of recurrent tumors, 
previously radiated tumors, and patients with neurofibromatosis type 2. There will be an 
allowance to enroll up to 95  patients to meet the goal of 90 subjects if subjects are withdrawn 
from the study due to a different pathologic entity diagnosed on biopsy of the tumor. 
Establishing the optimal dose and timing for FS will be a part of the feasibility study.  Flexibility 
will be allowed with the dose and timing to achieve optimal visualization condition based on 
surgeon feedbac k with a maximum cumulative dose of 500 mg ( standard dosage for 
ophthalmology angiography ). The study will be largely descriptive , documenting the 
macroscopic appearance of FS and describing surgeon observations with regards to timing of 
peak fluorescence, correlation with electrostimulation, and utility in differentiating normal 
tissue from tumor .  
17. Images  containing the tumor and facial and cochlear nerves  (or other relevant s tructures of 
interest in the case of meningioma, HNP, or HNS) will be captured with the microscope with the 
YE560 filter by the surgeon and analyzed; the YE560 filter will then be turned off and another identical image will be captured under white light microscopy for the separate survey validation 
analysis . For the RGB component image analysis, t he fluorescence  of the tumor will be 
measured in comparison to the facial nerve and cochlear nerve using ImageJ image analysis 
software to quantify the red, green,  and blue components of the images.  Inferential statistics 
will be used to compare the red, green, and blue components of regions of interest from the VS 
and the adjacent facial or cochlear nerve.  
18. For the survey validation analysis, we will validate the qu estion “How well did fluorescence 
correlate with your visual assessment of the tumor and nerve tissue under normal microscopy without the Yellow 560 filter?” The neurosurgeons and neurotologists will be presented with 30-
60 second videos  of the VS and faci al and/ or cochlear nerves, with and without  YE560 active . 
The surgeons will respond to the above question with choices of “no correlation,” “some 
correlation,” “good correlation,” and “excellent correlation.” Other questions from the surgeon 
survey will no t be validated due to  the scope of the feasibility study.  
3.6. Methodology   
3.6.1.  Investigational Type   
19. The current investigation is a feasibility study, to assess the usability of the YE560 option 
for visualization of FS during VS resection.  
20. 3.6.2.  Patients  
21. A total of 90 consenting patients, either male or female, clinically indicated for surgical resection 
of suspected VS, meni ngioma, HNP, HNS or recurrent VS, menigioma, HNP, or HNS will be part of 
the feasibility study phase.  Patients with neurofibromatosis type 2 and those receiving prior 
radiation therapy will not be excluded from the study.  
3.6.3.  Timeframe   
22. The estimated timeframe for enrol lment is approximately 18 months (from January  2019  – June  
2021).  
3.6.4.  Recruitment Process   
23. Patients under the care of the Clinical Investigators who are clinically indicated for surgical resection as a suspected VS , meni ngioma, or head and neck paraganglioma  or recurrent VS, 
meni ngioma, HNP, or HNS will be considered eligible for participation in the study. Each 
potential participant will be assessed against the inclusion and exclusion criteria. Potential 
patients shall be provided with plain language information about the study and will have the 
opportunity to ask questions of the study investigators. Informed consent shall be obtained by the Principal Investigator or Co -Investigators from eligible patients wishing to participate. Any 
patient that chooses not to p articipate in the study will undergo their indicated surgery with 
standard techniques, and their health care will not be compromised in any way. Patients shall be free to withdraw from the study at any time.  
3.6.5.  Inclusion Criteria   
Inclusion criteria shall be:  
• Patient with a s uspected VS , meni gioma, HNP or HNS  
• Recurrent VS , meni gioma, HNP, or HNS  with prior microsurgical  resection or radiation therapy 
• Clinical indication for microsurgical resection  
 
3.6.6.  Exclusion Criteria   
Exclusion criteria shall be:  
• Children (patients less than 18 years of age)  
• History of allergy to FS  
• History of renal failure  
• Pregnant women  
• Those with inability to give informed consent  
• Prisoners and inmates  
 
3.6.7.  Point of Enrollment   
Potential subjects will be provided with plain language information about the research  on the informed 
consent form , prior to signing the  consent form indicating their willingness to participate. The point of 
enro llment shall be upon clinical evaluation and consent for surgery . The patient shall be considered as 
part of the study population once they have undergone the YE560 visuali zation during the indicated 
microsurgery with confirmatory histopathology . Patients will be withdrawn from the study population if 
their final histopathology is not consis tent with vestibular schwannoma; this is expected to occur in less 
than 5% of subjects. Clinical data, intraoperative images, survey results and postoperative clinical data 
will still be maintained for these patients for potential case presentation or evaluation of bias.  
 
3.6.8.  Primary Endpoint   
Primary endpoint of this study will be an assessment of the utility of FS and YE560 via  survey of the 
operating surgeons.  
24. The primary outcome will be response to the question “ Based on the use and performance of FS 
in this case alone, how likely are you to use  FS in future cases (excluding the research trial)  
involving this tumor ?” We hypothesize that > 75% of responses will be “Plan to use in the 
majority of cases” or “Plan to use in all cases.”  
25. This primary outcome will be supported by responses assessing correlation of FS with 
electrostimulation and visual assessment using light microscopy using Likert -style ratings.  The 
responses to the latter correlation will be validated via presentation of fluorescence and white 
light microscopy images to the surgeons.  
 
3.6.9.  Secondary Endpoints   
The first secondary  endpoint is the differential measurement of red, green, and blue levels in VS tissue 
compared to the facial nerve and cochlear nerve using FS  and YE560. ImageJ software will be used to 
analyze representative images capture from microsurgery. The operating surgeon will delineate regions 
of interest for the VS, facial nerve, and cochlear nerve.  Separate similar analysis will be performed for 
othe r tumor types.  
 
The second secondary endpoint will incl ude gross total resection rate,  postoperative facial nerve 
function, and postoperative hearing status. Facial nerve function will be assessed by clinical evaluation at 3 month postoperative visits as well as intraoperative supramax imal  stimulation and minimum 
stimulation levels as routinely performed in surgery.  
 
3.6.10. Primary safety endpoints   
As FS is approved for the intravenous injection for ophthalmological applications and the safety profiles 
are well characterized and considered low risk . As described above the most common side effects are 
nausea and vomiting. This is side effect is commonly ex perienced with resection of vestibular 
schwannoma due to transection of the vestibular nerve and resulting vertigo. Thus, this side effect will 
not be tracked or reported. Other adverse effects of SF —urticaria, anaphylaxis, seizure, cardiac events, 
respiratory compromise —will be tracked and reported up to 3 months after surgery . The relevance of 
the adverse event to the administration of SF will be determined by the principal investigator.  
  
3.6.11. Microscope imaging during YE560 fluorescence use  
1. Standard methods of anesthesia as appropriate for open craniotomy or otologic surgery  will be used.  
2. Surgeons will gain access to the lesion of interest through a craniotomy or translabyrinthine 
approach.  
3. At the time of tumor exposure, p atients will be given intravenous FS. The timing and dose may vary. 
Maximum cumulative dose will not exceed 500 mg.  
• Initial dosing protocol will be 1 mg/kg intravenous FS. 
o If insufficient fluorescence is obtained or washout occurs, additional doses of 1 
mg/kg may be administered 
• Based on the experience of the first 3 cases, modifications to the dosing protocol may be made.  
o A higher, single dose may be administered if there is insufficient fluorescence or premature washout. Additional doses may be given during surgery.  
o If saturation of normal tissue with fluorescence occurs, the dose may be decreased or the FS may be administered at an earlier time  point (opening of 
dura, anesthesia induction, etc.)  during subsequent cases  
• Continued adjustments may be made to the dosing and timing, with a goal of standardizing the dose after 10 cases  
4. Once the VS  has been surgically exposed and FS has been administered, the YE560 fluorescence 
module shall be used to visualize fluorescence in the tissue. Images will be captured prior to tumor dissection, after exposure of the intracapsular tumor contents, and after maximum resection.  A pair of 
image s—one using the YE560 and one with white light microscopy —will be captured during each event.  
5. With the YE560 turned on, images will be captured with the microscope.  Video recording from the 
Pentero 900 and Kinevo 900 microscopes will be captured for the n entirety of their use in the case.  
6. The time from injection until to the point where the differential fluorescence is greatest  will be 
reco rded and documented in the surgeon’s survey . Circulating nursing staff will record timestamps in 
collaboration with instruction from the operating surgeons.  
7. The YE560 module will be applied during the aforementioned events and additionally at the discretion 
of the operating surgeons . Depending upon the number of potential regions identified for imaging and 
for possible biopsies, the YE560 fluorescence module is expected to add less than 10 minutes to the overall procedure.  
8. At any time, the operating surgeon may turn off the YE560 module as dictated by the needs of surgery.  
9. Following completion  of tumor resection and prior to closing of the dura, supramaximal and minimum 
stimulation values will be obtained  (if relevant), as is standard practice with vestibular schwannoma 
microsurgery at our institution. The process is as described in Schmitt et al. (2013). In brief, transcutaneous bipolar electrodes are used at the extratemporal main trunk of the facial nerve to stimulate the nerve at 100 msec pulses increasing from 0 mA until a plateau amplitude compound muscle action potential is obtained. A Pr ass probe is used to stimulate the facial nerve proximal to the 
tumor (at the brainstem if possible) at increasing current (starting at 0 mA) until a plateau of CMAP is obtained. The ratio of these amplitude responses is calculated and subtracted from 1 to  calculate the 
supramaximal stimulation. The minimum stimulation is the minimum current level at which a reliable facian nerve response can be obtained with proximal stimulation of the facial nerve using the Prass probe.  
11. Suspected lesions that are foun d to be a histopathological entity  excluded from this study  after 
microsurgical resection and biopsy will be withdrawn from the study.  
12. Post –procedure data analysis will include  analysis of surgeon survey responses and, red/green/blue 
component analysis  using ImageJ software . Additional data (demographics, imaging characteristics, 
facial nerve and audiometric data) will be reviewed and recorded from preoperative and 3 month 
postoperative visits. Video recordings will be edited to 30 -60 second videos following the case with 
representative views of the VS, facial nerve and cochlear nerve with and without the YE560 active. These 
edited videos will be used for the aforementioned surgeon validation study rating the correlation of fluorescence with w hite light microscopy.  
13. Upon completion of surgery, operating surgeons will complete the remainder of the paper survey 
(Appendix 3).  The surveys will be collected, with responses logged in the Rave database. The paper 
surveys will be stored in a secure location in the Otolaryngology department. 
3.7. Informed Consent Process   
Patients  under the care of the study investigators will be provided with the written informed consent 
form with plain language information about the research. The study will be explained to potential 
subjects, and they will be advised that participation is voluntary. Potential subjects will have the 
opportunity to ask ques tions of the study investigator before agreeing to participate and signing the 
consent form. Patients will not be coerced into the study. Any patient that chooses not to consent will undergo the standard microsurgical procedure and their health care will n ot be compromised in any 
way. Patients shall be free to withdraw from the study at any time.  
3.8. Monitoring and Execution of the Trial   
The Sponsor’s Obligations are outlined in Appendix 1 of this documen t.  
The Investigator’s Agreement and Obligations are outlined in Appendix 2 of this document  
The results, progress and execution of the feasibility study will be monitored as outlined in chapter 
4.5.10 ( Microscope imaging during YE560 fluorescence use).  
Carl Zeiss Meditec, Inc. (or designee)  
5160 Hacienda Drive  
Dublin, CA 94568  
 The clinical investigation team will meet quarterly during active enrollment to review enrollment, current outcomes and any a dverse events.  
3.9. Record Keeping  
Clinical investigators shall keep a record of subjects recruited in a secure database  and/or spreadsheet , 
and study participation will be recorded in each patient’s medical case notes stored by the hospital. Case report forms, images and other associated procedure data labelled with the patient’s 3 digit code shall be provided to the Sponsor for analysis and back up. All required records will be stored by the Sponsor and Investigators for a period of 3 years after completion of the study.  
4. Description of the Medical Device under Investigation  
4.1. Manufacturer   
Carl Zeiss Meditec AG  
Goeschwitzer Strasse 51 -52  
07745 Jena/Germany  
4.2. Item/Part Number   
The microscope equipped with the YE560 fluorescence module for clinical evaluation comprises:  
• Surgical Microscope  
 Name: Kinevo 900  
 
• Fluorescence module  
 
Name: YELLOW 560  REF: 303582- 9205- 000  
• Still Image and Video recording  
 
Name: Video Recordi ng HD  
REF: 303582- 9700- 000 
 
• Capturing device  
Name: High Definition Camera 3CCD NTSC  
REF: 303581- 9764- 000  
4.3. Intended Purpose of this Device   
The Kinevo 900  with YE560 fluorescence option is a surgical micr oscope equipped with an visualization 
tool to detect fluorescence signals in a wave leng th range between 540nm to 690nm .  
4.4. Clinical Indications & Contraindications for use in Study   
The clinical indication for use of the YE560 fluorescence module in the proposed study is neurological pathology requiring open craniotomy  or translabyrinthine otologic approach.  
Use of the YE 560 fluorescen ce option is contra- indicated in patients where the tumor resection bed is 
not directly surgically exposed and cannot be visualized with the surgical microscope .  
A fluorescent contrast agent, FS will be administered intravenously within its labeled dose range for its 
approved use in ophthalmic applications to reveal fluorescence contrast during the use of YE560. Occasionally patients may experience adverse events. The fluorescein dye can rarely cause allergic reactions. Fluorescein dye is a FDA -approved medicine that is routinely used by ophthalmologists (eye 
doctors) to perform exams of the retina of the eye. Administration of Fluorescein is contraindicated in patients with:  • Known allergy or prior adverse reaction to Fluorescein  • Women who are pregnant or breastfeeding  
 
4.5. Summary of Device Design   
The Instruction for use  covers basic set -up and use of the KINEVO 900  equipped with YE560 
fluorescence option  The YE560 option is an accessor y for intra- Figure 1  operative illumination of the surgical field with light 
of a wavelength between 460nm and 690nm.  The integrated fluorescence module YE560 serves to make fluorescent areas visible. It is designed for stimulus light penetrating the service in a wave length range from 460nm to 500nm and for visualizing the YE560 fluorescence light reflected by the service in a wave length range of 540nm to 690nm. Surgeons can switch between white light and fluorescence mode. Blue excitation light should be dimmed for optimum reproduction of the fluorescence light.  
The YE560 lighting option can be operated from the hand grip or foot switch. The user manual explains 
how to set-up, operate and record images taken with the YE560 module.  
 
5. Training and Experience Requirements for use of the Device   
The Instruction for use covers basic set -up and use of the YE560 fluorescence option as well as recording 
function for captu ring pictures. Training  in the use of YE560  for all operating surgeons  in this study will 
be provided by the Sponsor representative before use in surgery on enrolled subjects . A training log 
documenting personel and training dates will be kept by the study  coordinator. All st udy cases will be 
assisted by a sponsor representative.  
6. Description of Medical/Surgical Procedures involved in the use of 
the device  
The YE560 fluorescence option will be used during open craniotomy procedures performed for the 
purpose of tumor resection and possible biopsy. Standard neurosurgical techniques shall be used 
throughout the procedure. The YE560 fluorescence will be used during the surgery, once the tumor is exposed. The YE560 fluorescence visuali zation option can be turned on/off during the tumor resection 
phase of the surgery. Images captured with the KINEVO  900 under YE560 light and simultaneously 
navigation pictures, represen ting the location of the biopsy during surgery will be linked to the biopsy 
results available after surgery. To obtain images, a fluorescent contrast agent is required. Fluorescein Sodium will be administered intravenously prior to imaging within its labelled dose range for its approved use in ophthalmic applications to reveal fluorescence contrast during the use of YE560.  
7. Study Drug   
7.1. Description  
AK-FLUOR ® (fluorescein injection, USP) 10% contains fluorescein sodium (equivalent to fluorescein 10% 
w/v). It is a sterile solution for use intravenously as a diagnostic aid. Its chemical name is spiro[isobenzofuran -1(3H), 9'-[9H]xanthene] -3-one, 3'6' -dihydroxy, disodium salt. The active ingredien t 
is represented by the chemical structure (Figure 2):  
 
 
Figure 2 Fluorescein 10%  
AK-Fluor ® (fluorescein injection, USP) 10% is supplied as a sterile, unpreserved, single -use aqueous 
solution, that has a pH of 8. 0 - 9.8 and an osmolality of 572 -858 mOsm /kg. Active ingredient: fluorescein 
sodium Inactive Ingredients Sodium hydroxide and/or hydrochloric acid (to adjust pH), and water for injection.  
7.2. Method for Assigning Subjects to Study Group   
Patients under the care of the Clinical Investigators who are clinically indicated for surgical resection as a 
suspected VS or recurrent VS will be considered eligible for participation in the study . Investigators will 
determine if patients are eligible for the study during clinic appointments. Each potential participant will 
be assessed against the inclusion and exclusion criteria. Potential participants  shall be provided with 
plain language information about the study  on the IRB -approved consent form  and will have the 
opportunity to ask questions of the study investigators. Informed consent shall be obtained by the 
Principal Investigator,Co -Investigators , or research coordinator  from eligible patients wishing to 
partic ipate. Any patient who  chooses not to participate in the study will undergo their indicated 
microsurgery  with standard techniques, and their health care will not be compromised in any way. 
Participants  shall be free to withdraw from the study at any time. Participants will be withdrawn if their 
intraoperative biopsy yields an entity other than VS.  
7.3. Preparation and Administration of Study Drug  

The preparation and administration of fluorescein sodium is coordinated and executed by the 
anaesthesiologist responsible during the surgery  according to dosage and administration recommended 
indicated by the product insert.  
7.4. Subject Compliance and Ad verse Event Monitoring   
7.4.1. Adverse Event Monitoring  
Adverse events (AEs) must be reported on the Adverse Event Form (AEF). Adverse events that will be 
monitored include urticaria, anaphylaxis, respiratory compromise, cardiac events, seizure, and death. These events will be monitored in the first 3 months after surgery.  Complete clearance of SF is expected 
within 72 hours, and associated adverse e vents, if any, are anticipated within that timeframe. After 
discharge from the hospital, any reporting of adverse events will rely upon participants contacting the research team prior to the scheduled 3 month follow up.  Nausea and vomiting will not  be include d as an 
adverse event as these symptoms are expected outcomes from surgery.  
If adverse events occur, the first concern will be the safety and welfare of the patient. Appropriate medical intervention will be made. Any adverse events observed by the Investigator or reported by the patients will be recorded in the appropriate section of the patient’s Case Report Form (CRF) as well as on an Adverse Event Form .  
The Investigator must categorize each AE by degree of harm to the patient (mild, moderate, or ser ious), 
and the relationship to study device (not related, possibly, probably, or definitely) in the Adverse Event Form. Adverse events observed will be captured on the Adverse Event Follow- up Form and the CRF until 
such time the adverse event is reported as resolved, or for the course of the study if the event does not resolve.  
A serious adverse event includes any prolong hospitalization, and any event that is life -threatening, 
results in permanent impairment of a bodily function or permanent damage to a body structure, or an event that necessitates medical or surgical interventi on to preclude such permanent impairment or 
permanent damage.  
Changes in any chronic condition or disease that are consistent with natural disease progression are not considered AEs and will not be recorded on an AE CRF . 
Medical treatment related to any a dverse events will not be paid for by the study, Mayo Clinic, or the 
Sponsor. Patients and their insurance will be billed for any treatments or encounters associated with an 
adverse event.  
7.4.2. Adverse Event Reporting   
Any serious adverse events, whether unanticipated or not, and whether or not ascribed to study device, will be communicated promptly to Carl Zeiss Meditec Inc and to the IRB. These reports must be 
confirmed in writing within 5 days of the occurrence.  
7.5. Packaging   
FS usually comes in a package of twelve vials. Ak-fluor ® (fluorescein injection, USP) 10% is supplied in a 
single -use 5 mL glass vial with a gray bromobutyl serum siliconized stopper and orange flip -off cap . It 
contains a sterile, dark -reddish orange  solution of fluorescein sodium.  
7.6. Receiving, Storage, Dispensing and Return   
7.6.1.  Receiving of Drug Supplies   
FS is currently available in the local pharmacy in the hospital. The supply during the course of this study 
will be coordinated as part of the regular drug supply in the OR  
7.6.2.  Storage   
AK-Fluor ® (fluorescein injection, USP) 10% will be temporarily storage at 2° - 25°C (36° - 77°F) in the 
sterile court for study cases in the OR.  
7.6.3.  Dispensing of Study Drug   
The drug is currently available in the local pharmacy of the hospital. The Saint Mary’s Hospital OR 
Pharmacy Managers  will be informed of the need for drug in the OR during the IRB approval process.  
The OR pharmacy will dispense the drug to the anesthesiologist or certified nurse anesthetist 
participating in the case.   
7.6.4.  Return or Destruction of Study Drug  
Fluorescein residual in a vial that was not used during the study procedure will be destructed.  
8. Clinical Investigation and Documentation  
8.1. Requirements before Starting the Clinical Investigation  
• CIP written and signed  
• Approval of ethics/IRB committee obtained  
 
8.2. Training and Information for Clinical Investigators   
The sponsor shall pr ovide training for clinical investigators covering:  
• YE560 fluorescence features available on the microscope  
• YE560 module set up  
• Turn on/off the YE560 module during surgery  
• Contrast agents and clinical workflows  
• Recording videos and capturing pictures during surgery  
• Software operation  
• Reviewing, managing and backing up procedure data (e.g. videos pictures)  
 
8.3. Investigator and Sponsor File Maintained   
• Clinical Investigation Plan  • CV for each clinical investigator  
• Ethics committee approval and correspondence  
• Correspondence with authorities required by national legislation  
• Agreement between investig ators and sponsor  
• Insurance certificates  
• Informed consent forms and information provided to subjects  
• Case report forms  
• Forms for reporting adverse events and adverse device effects  
• Names and contact addresses of the monitor  
 
8.4. Final Repo rt  
• Signed principal clinical investigator  
• Available to all clinical investigators and the ethics committee  
• Includes thorough identification of device  
• Description of the methodology  
• Design of clinical investigation  
• Summary of the Clinical Investigation Plan and any deviations  
• Data analysis with any statistical analyses (if applicable)  
• Critical appraisal relating to aims of the investigation  
  
APPENDIX 1   
Sponsor’s Obligations  
Responsibilities of Sponsors  
General responsibilities of Sponsors  
Sponsors are responsible for providing investigators with the information they need to conduct the investigation 
properly . 
Specific responsibility of Sponsors  
1. Obtaining agreements . A Sponsor shall obtain from each participating Investigator a signed agreement that 
includes:  
 A statement of the Investigator’s commitment to:  
I. Conduct the investigation in accordance with the agreement, the investigational plan, this part and other 
applicable FDA regulations, and conditions of approval imposed by the reviewing IRB or FDA;  
II. Supervise all testing of the device involving human subjects; and  
III. Ensure that the requiremen ts for obtaining informed consent are met (21CFR Part 50).  
 
Sponsor Records  
A Sponsor shall maintain the following accurate, complete, and current records relating to an investigation for  
a period of 3 years after completion of the study:  
1. All corres pondence with an Investigator, an IRB, or FDA, including required reports.  
2. Records of shipment. Records of shipment shall include the name and address of the consignee, type and 
quantity of device, date of shipment, and serial number.  3. Signed Investigator agreements.  4. Records concerning adverse device effects (whether anticipated or unanticipated) and complaints.  
5. Any other records that FDA requires to be maintained by regulation or by specific requirement for a category of 
investigation or a particular investigation.   
Sponsor Reports  
A Sponsor shall prepare and submit the following complete, accurate, and timely reports:  
1. Unanticipated adverse device effects. A Sponsor who conducts an evaluation of an unanticipated adverse device 
effect shall report the results of such evaluation to FDA and to all reviewing IRBs and participating Investigators 
within 10 working days after the Sponsor first receives notice of the effect. Thereafter the Sponsor shall submit 
such additional reports concerning the effect as FDA requests.  
2. Withdrawal of IRB approval. A Sponsor shall notify FDA and all reviewing IRBs and participating Investigators of 
any withdrawal of approval of an investigation or a part of an investigation by a reviewing IRB within 5 working 
days after receipt of the withdrawal of approval.  
3. Withdrawal of FDA approval. A Sponsor shall notify all reviewing IRBs and participating Investigators of any 
withdrawal  of FDA approval of the investigation, and shall do so within 5 working days after receipt of notice of the 
withdrawal of approval.  
4. Progress reports . At regular intervals, and at least yearly, a Sponsor shall submit progress reports to all reviewing 
IRBs.  
  
APPENDIX 2   
Investigator’s Agreement and Obligations  
Responsibilities of Investigators  
General responsibilities of Investigators  
An Investigator is responsible for ensuring that an investigation is conducted according to the signed agreement, 
the investigational plan and applicable FDA regulations, for protecting the rights, safety, and welfare of subjects under the Investigator’s c are, and for the control of devices under investigation. An Investigator also is responsible 
for ensuring that informed consent is obtained in accordance with 21 CFR part 50.  
 Study staff will meet on a quarterly basis to debrief and assess progress, with email contact in the interim as 
needed.  Meeting outcomes will be documented and available to study staff.  
 
Specific responsibilities of Investigators  
1. Awaiting approval. An Investigator may determine whether potential subjects would be interested in 
participating in an investigation, but shall not request the written informed consent of any subject to participate, 
and shall not allow any subject to participate before obtaining IRB approval.  
2. Subject Qualification. The Investigator is responsible for ensuring that all subjects entering the study conform to 
the patient selection criteria.  
3. Compliance. An Investigator shall conduct an investigation in accordance with the signed agreement with the 
Sponsor, the invest igational plan, all applicable FDA regulations, and any conditions of approval imposed by an IRB 
or FDA.  
 
Investigator Records  
A participating Investigator shall maintain the following accurate, complete, and current records relating to the 
Investigator’ s participation in an investigation for a period of 3 years after completion of the study:  
1. All correspondence with another Investigator, an IRB, the Sponsor, or FDA, including required reports.  
2. Records of each subject’s case history and exposure to  the device. Case histories include the case report forms 
and supporting data including, for example, signed and dated consent forms and medical records. Such records 
shall include:  a) Documents evidencing informed consent.  
b) All relevant observations, including records concerning adverse device effects (whether anticipated or 
unanticipated), information and data on the condition of each subject upon entering, and during the course of, the investigation, including information about relevant previous medi cal history and the results of all diagnostic tests.  
3. The protocol, with documents showing the dates have and reasons for each deviation from the protocol.  
4. Any other records that FDA requires to be maintained by regulation or by specific requirement  for a category of 
investigations or a particular investigation.  
 
Investigator Reports  
The Investigator shall prepare and submit the following complete, accurate, and timely reports:  
1. Unanticipated adverse device effects. An Investigator shall submit to the Sponsor and to the reviewing IRB a 
report of any unanticipated adverse device effect occurring during an investigation as soon as possible, but in no 
event later than 10 working days after the Investigator first learns of the effect.  
2. Withdrawal of IRB approval. An Investigator shall report to the Sponsor, within 5 working days, withdrawal of 
approval by the reviewing IRB of the Investigator’s part of an investigation.  
3. Deviations from the investigational plan. An Investigator shall document report to the Sponsor any deviation 
from the investigational plan.  
4. Informed consent. If  an Investigator enrolls a subject without obtaining informed consent, the Investigator shall 
report such use to the Sponsor and the reviewing IRB within 5 working days after the use occurs.  
5. Final report. The Investigator shall complete a final report.   
6. Other. The Investigator shall, upon request by a reviewing IRB, provide accurate, complete, and current  
 
information about any aspect of the investigation.  
APPENDIX 3  
Surgeon Survey  
 
